27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Of 300 randomized participants, 277 participants (mean age, 72.9 years; 69.3% female) were included in the modified intention-to-treat analysis (142 in the MLI group and 135 in the control group). 5 key findings →
Design: randomized controlled trial Participants: 277 Evidence: high
Full summary, score breakdown and related studies → Original source
There is consistent evidence supporting an association between AF and increased incidence of dementia in patients with stroke whereas there remains considerable uncertainty about any link in the broader population. 5 key findings →
Design: meta-analysis Participants: 46,637 Evidence: high
Full summary, score breakdown and related studies → Original source
A total of 20 studies were included in the systematic review, and 17 provided data for the meta-analysis. 5 key findings →
Design: systematic review Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source
Presence and severity of WMH are associated with substantially increased risk of dementia, functional impairment, stroke recurrence, and mortality after ischemic stroke. 5 key findings →
Design: meta-analysis Participants: 104 Evidence: high
Full summary, score breakdown and related studies → Original source
Following reports of meningoencephalitis (overall 18/300 [6%]), immunization was stopped after one (2 patients), two (274 patients), or three (24 patients) injections. 3 key findings →
Participants: 300 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The incidence rate of dementia in Europe and North America has declined by 13% per decade over the past 25 years, consistently across studies. 2 key findings →
Design: cohort study Participants: 49,202 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Galantamine failed to significantly influence conversion to dementia. 3 key findings →
Participants: 2,048 Evidence: high
Full summary, score breakdown and related studies → Original source
Resveratrol was safe and well-tolerated. 4 key findings →
Design: clinical trial Participants: 119 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
As the first 1-year, multinational, double-blinded, placebo-controlled study of a cholinesterase inhibitor in AD, these data support donepezil as a well tolerated and effective long-term treatment for patients with AD, with benefits over placebo on global assessment, cognition, and ADL. 3 key findings →
Participants: 286 Evidence: high
Full summary, score breakdown and related studies → Original source
A total of 917 participants had a mean baseline age of 67.4 years (SD 12.1), 49.4% were female, and 48.6% self-identified as Black. 5 key findings →
Design: cohort study Participants: 30,239 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Antihypertensive use was associated with decreased AD but not non-AD risk throughout late life. 5 key findings →
Design: meta-analysis Participants: 31,250 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Though still small, the current body of RCT evidence indicates that CT is safe and modestly effective on cognition in patients with mild to moderate PD. 4 key findings →
Participants: 272 Evidence: high
Full summary, score breakdown and related studies → Original source
Our objectives were to investigate the utility of the Hachinski Ischemic Score (HIS) in differentiating patients with pathologically verified Alzheimer's disease (AD), multi-infarct dementia (MID), and "mixed" (AD plus cerebrovascular disease) dementia, and to identify the specific items of the HIS that best discriminate those dementia subtypes. 4 key findings →
Design: meta-analysis Participants: 312 Evidence: high
Full summary, score breakdown and related studies → Original source
Among 91,881 participants (mean age 59.3 at baseline, 55.0% female participants), 16,507 incident ADRD cases were identified from Medicare claims (1999-2016, mean follow-up 9.3 years). 5 key findings →
Design: cohort study Participants: 91,881 Evidence: moderate
Full summary, score breakdown and related studies → Original source
These findings reveal the potential for anti-Aβ therapies to compromise long-term brain health by accelerating brain atrophy and provide new insight into the adverse impact of ARIA. 4 key findings →
Design: systematic review Participants: 8,062 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
There was no evidence that aspirin was effective in reducing risk of dementia, MCI, or cognitive decline. 2 key findings →
Participants: 19,114 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The cognitive impairment cohort (n = 14,175) included participants without evidence of impairment at baseline who underwent follow-up testing. 3 key findings →
Design: cohort study Participants: 14,175 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Greater MIND diet adherence was associated with decreased risk of cognitive impairment in female participants but not male participants, with no difference between Black participants and White participants. 5 key findings →
Design: cohort study Participants: 14,145 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Based on this meta-analytic survey of the literature, increased amyloid burden has small but nontrivial associations with specific domains of cognitive performance in individuals who are currently cognitively normal. 3 key findings →
Design: meta-analysis Participants: 7,140 Evidence: high
Full summary, score breakdown and related studies → Original source
Diuretic, ARB, and ACE-I use was, in addition to and/or independently of mean systolic blood pressure, associated with reduced risk of AD dementia in participants with normal cognition, while only diuretic use was associated with reduced risk in participants with MCI. 5 key findings →
Design: longitudinal study Participants: 1,928 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Comparable modest reductions in agitation occurred in patients receiving haloperidol, trazodone, BMT, and placebo. 4 key findings →
Participants: 149 Evidence: high
Full summary, score breakdown and related studies → Original source
Then, voxel-wise brainwide association analyses were used to identify gray matter volumes (GMVs) associated with social isolation and with loneliness. 5 key findings →
Design: cohort Participants: 462,619 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Older adults with higher triglyceride levels within the normal to high-normal range had a lower dementia risk and slower cognitive decline over time compared with individuals with lower triglyceride levels. 5 key findings →
Design: randomized controlled trial Participants: 13,976 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A healthy lifestyle as a composite score is associated with a substantially lower risk of Alzheimer's dementia. 5 key findings →
Design: meta-analysis Participants: 1,845 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The number of people in the United States with AD dementia will increase dramatically in the next 40 years unless preventive measures are developed. 1 key finding →
Design: longitudinal study Participants: 1,913 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →